← All trials
NCT07149753
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2026
- Primary completion
- Jul 20, 2026
- Completion date
- Aug 30, 2026
- First posted
- Sep 2, 2025
- Last posted
- Sep 8, 2025
- Enrollment
- 15
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Industrial de SantanderLead sponsor
- Fundación Oftalmológica de Santander Clínica Carlos Ardila LulleCollaborator
- Universidad Industrial de SantanderOfficial
- Universidad Industrial de SantanderSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.